Back to top
Top

All eCQMs associated with: Management of Chronic Conditions

Year Type CMS eCQM ID Measure Name
2022 EP/EC CMS122v10 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
2020 EP/EC CMS122v8 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
2021 EP/EC CMS122v9 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
2022 EP/EC CMS131v10 Diabetes: Eye Exam
2020 EP/EC CMS131v8 Diabetes: Eye Exam
2021 EP/EC CMS131v9 Diabetes: Eye Exam
2022 EP/EC CMS133v10 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
2020 EP/EC CMS133v8 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
2021 EP/EC CMS133v9 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
2022 EP/EC CMS134v10 Diabetes: Medical Attention for Nephropathy
2020 EP/EC CMS134v8 Diabetes: Medical Attention for Nephropathy
2021 EP/EC CMS134v9 Diabetes: Medical Attention for Nephropathy
2022 EP/EC CMS135v10 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2020 EP/EC CMS135v8 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2021 EP/EC CMS135v9 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2022 EP/EC CMS143v10 Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
2020 EP/EC CMS143v8 Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
2021 EP/EC CMS143v9 Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
2022 EP/EC CMS144v10 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2020 EP/EC CMS144v8 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)